Pancreas Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
14492B Molecular Determinants of Malignancy in Pancreatic Cystic Neoplasms
Select
16866B A Phase I Study of Stereotactic Body Radiation Therapy in Patients with Unresected Adenocarcinoma of the Pancreas or Ampulla
Select
12-0033 A genotype-guided dosing study of mFOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
12-0159 A Pilot Study of neoadjuvant and adjuvant mFOLFIRINOX in localized, resectable pancreatic adenocarcinoma
Select
IRB13-0585 A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
Select
IRB13-0927 A phase I open-label, non-randomized, dose-escalation firstin-man trial to investigate the c-Met kinase inhibitor EMD 1214063 under two different regimens in subjects with advanced solid tumors
Select
IRB13-1267 A Phase IIB, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-treated Metastatic Pancreatic Adenocarcinoma
Select
IRB13-1503 A Phase 3, Multicenter, Open-Label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0595 A genotype-guided dosing study of FOLFIRABRAX in previously untreated patients with advanced gastrointestinal malignancies
Select
IRB14-0660 A Randomized, Double-blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team